Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Altimmune, Inc. | a09-35047_2ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 9, 2009
PHARMATHENE, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-32587 |
|
20-2726770 |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
One Park Place, Suite 450, Annapolis, Maryland |
|
21401 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number including area code: (410) 269-2600
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure
On December 9, 2009, PharmAthene, Inc. (the Company) hosted a conference call for investors to provide an update on its recombinant protective antigen anthrax vaccine program. Attached as Exhibit 99.1 to this Current Report on Form 8-K is a transcript of such call. Any information contained in this transcript should be read in the context of and with due regard to the more detailed information provided in other documents we file with or furnish to the Securities and Exchange Commission.
In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including the attached Exhibit 99.1, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Transcript of December 9, 2009 Investor Conference Call |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PHARMATHENE, INC. |
|
|
(Registrant) |
|
|
|
|
|
|
|
Date: December 9, 2009 |
By: |
/s/ Jordan P. Karp |
|
|
Jordan P. Karp |
|
|
Senior Vice President, General Counsel and Secretary |
3